Prenetics became the first Hong Kong unicorn to list on Nasdaq, and its shares began trading on May 18 under the ticker “PRE”.
As the Chief Financial Officer of the company, Stephen Lo witnessed the transformation of Prenetics, from a Hong Kong start-up to global leading genomics and diagnostic company. “We live by our mission - decentralising and disrupting healthcare - which has enabled us to play a key role in the fight against the COVID-19 pandemic, save lives, and prevent genetic and infectious diseases.”
Reflecting on the IPO journey, Stephen shared, “Today is a moment of celebration, but we will not rest. We have unfinished business. There are significant opportunities to improve the healthcare system, making healthcare more accessible to patients, at their homes, and globally. Getting listed is a key milestone of Prenetics, but it is my conviction that this is just the beginning. With the support and synergies of Dr. Adrian Cheng's network, I am very excited by what's ahead of Prenetics.”
Stephen has served as the Chief Financial Officer of Prenetics since 2018. He oversees the financial operations, corporate accounting and reporting, treasury, financial and tax planning and analysis, and investor relations. Before joining Prenetics, he was in the Asia Pacific Investment Banking team of Citigroup, where he worked extensively on IPO transactions, placements, debt issuances, and cross-border mergers and acquisitions in Asia and the US between 2014 and 2018. From 2007 to 2011, he was an auditor with Ernst & Young.
Stephen received a Master of Business Administration from Yale University’s School of Management, a Master of Science in Accounting and Finance from the London School of Economics and Political Science, and a Bachelor of Business Administration in Accounting from Hong Kong Baptist University. He is a Fellow of the Hong Kong Institute of Certified Public Accountants and a CFA Charter holder.
Congratulations Stephen, on the successful listing!